Arena Pharmaceuticals (FRA:RN3N) Net Issuance of Preferred Stock : €0.00 Mil (TTM As of Dec. 2021)

View and export this data going back to 2000. Start your Free Trial

What is Arena Pharmaceuticals Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Arena Pharmaceuticals's net issuance of preferred for the three months ended in Dec. 2021 was €0.00 Mil. The number is 0, which means that Arena Pharmaceuticals has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Arena Pharmaceuticals's net issuance of preferred for the trailing twelve months (TTM) ended in Dec. 2021 was €0.00 Mil.

Arena Pharmaceuticals Net Issuance of Preferred Stock Historical Data

The historical data trend for Arena Pharmaceuticals's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arena Pharmaceuticals Net Issuance of Preferred Stock Chart

Arena Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Net Issuance of Preferred Stock

Get a 7-Day Free Trial

Arena Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Net Issuance of Preferred Stock	Get a 7-Day Free Trial															-	-	-	-	-

Arena Pharmaceuticals Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Arena Pharmaceuticals Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Arena Pharmaceuticals's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Arena Pharmaceuticals (FRA:RN3N) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arena Pharmaceuticals Inc (FRA:RN3N) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Heber Avenue, Suite 204, Park City, UT, USA, 84060

Website

https://www.arenapharm.com

Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.

Arena Pharmaceuticals (FRA:RN3N) Headlines

No Headlines